Advanced in Squamous Cell Lung Carcinoma

Dongqing M. Lv

Linhai, CN 
Advanced in Squamous Cell Lung Carcinoma
Linhai, CN 
OverviewLocationsClinical Research

Overview

Dongqing Lv practices in Linhai, China. Lv is rated as an Advanced expert by MediFind in the treatment of Squamous Cell Lung Carcinoma. Their top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC).

Their clinical research consists of co-authoring 83 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Squamous Cell Lung Carcinoma.

Locations

Linhai, China
Other Locations
Taizhou, China
Wenzhou, 317000, China
Xuzhou, China
Zhejiang Key Laboratory Of Aquatic Germplasm Resources, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
Enrollment Status: Unknown
Publish Date: March 08, 2023
Intervention Type: Drug
Study Drugs: Pyrotinib, Docetaxel
Study Phase: Phase 3
S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer：An One-arm, Phase Ⅱ, Multi-center Clinical Study (SALTER TRIAL)
S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer：An One-arm, Phase Ⅱ, Multi-center Clinical Study (SALTER TRIAL)
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: S1+Anlotinib
Study Phase: Phase 2
View 1 Less Clinical Trial

83 Total Publications

Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lv's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile